The global market for complement 3 glomerulopathy (c3g) treatment is poised for steady growth, with a projected valuation of ...

Pegcetacoplan substantially reduced proteinuria in these potentially debilitating rare kidney diseases in a new phase 3 study ...

During the trial, patients treated with Fabhalta experienced a significant reduction in proteinuria as early as two weeks.

Novartis yesterday presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney ...

1 About C3 glomerulopathy (C3G) C3G is an ultra-rare, progressive kidney disease that initially presents mostly in children and young adults.3,4,9 Each year, approximately 1-2 people per ...

Background: C3 Glomerulopathy (C3G) is a complement-mediated disease, with predominant C3 deposits, where pathogenic genetic variants in complement system components and circulating autoantibodies ...

Our medicines reach more than 250 million people worldwide. Smith RJ, Kavanagh D, Vivarelli M, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-Month results from the ...

announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the treatment of complement 3 glomerulopathy (C3G).